Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Sven Rohmann | M | 62 |
Inprother ApS
 Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | 1 jaar |
| Nicolaj Højer Nielsen | M | - |
Inprother ApS
Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | 6 jaar |
| J. Robert Coleman | M | - |
Inprother ApS
Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Jordi Naval | M | - |
Inprother ApS
Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | 2 jaar |
| Kim Arvid Nielsen | M | 65 |
Inprother ApS
Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Denemarken | 5 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Peter Johannes Holst
- Persoonlijk netwerk
